anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Diclofenac, a widely used non-steroidal anti-inflammatory drug, can cause liver damage via its metabolic activation by hepatic CYP450s and UGT2B7. Fasting can affect drug-induced liver injury by modulating the hepatic metabolism, but its influence on diclofenac hepatotoxicity is unknown. Thus, we investigated diclofenac-induced liver damage after fasting in mice, and the cellular events were examined. Male ICR mice fasted for 16 h showed the elevation of CYP3A11, but the decreases of UGT2B7, glutathione (GSH), and GSH S-transferase-μ/-π levels in the livers. Diclofenac (200 mg/kg) injection into the mice after 16-h fasting caused more significant liver damage compared to that in the diclofenac-treated fed mice, as shown by the higher serum ALT and AST activities. Diclofenac-promoted hepatic oxidative stress (oxidized proteins, 4-hydroxynonenal, and malondialdehyde), endoplasmic reticulum (ER) stress (BiP, ATF6, and CHOP), and apoptosis (cleaved caspase-3 and cleaved PARP) were enhanced by fasting. Autophagic degradation was inhibited in the diclofenac-treated fasting mice compared to that of the corresponding fed mice. The results suggest that fasting can make the liver more susceptible to diclofenac toxicity by lowering GSH-mediated detoxification; increased oxidative/ER stresses and apoptosis and suppressed autophagic degradation may be the cellular mechanisms of the aggravated diclofenac hepatotoxicity under fasting conditions.
Aerodynamically light particles incorporating a surfactant on the surface thereof for drug delivery to the pulmonary system, and methods for their synthesis and administration are provided. In a preferred embodiment, the aerodynamically light particles are made of a biodegradable material and have a tap density less than 0.4 g/cm3 and a mass mean diameter between 5  mu m and 30  mu m. The particles may be formed of biodegradable materials such as biodegradable polymers. For example, the particles may be formed of poly(lactic acid) or poly(glycolic acid) or copolymers thereof. Alternatively, the particles may be formed solely of the drug or diagnostic agent and a surfactant. Surfactants can be incorporated on the particle surface for example by coating the particle after particle formation, or by incorporating the surfactant in the material forming the particle prior to formation of the particle. Exemplary surfactants include phosphoglycerides such as L- alpha -phosphatidylcholine dipalmitoyl. The aerodynamically light particles incorporating a therapeutic or diagnostic agent and a surfactant may be effectively aerosolized for administration to the respiratory tract to permit systemic or local delivery of wide a variety of therapeutic agents.
OBJECTIVE: To explore the relationship between serum calcium levels and the prognosis of severe acute osteomyelitis, and to assess the effectiveness of calcium levels in prognostic evaluation.
METHODS: Relevant patient records of individuals diagnosed with severe acute osteomyelitis were obtained for this retrospective study from the Medical Information Mart for Intensive Care (MIMIC-IV). The study aimed to assess the impact of different indicators on prognosis by utilizing COX regression analysis. To enhance prognostic prediction for critically ill patients, a nomogram was developed. The discriminatory capacity of the nomogram was evaluated using the Area Under the Curve (AUC) of the Receiver Operating Characteristic (ROC) curve, in addition to the calibration curve.
RESULT: The study analyzed a total of 1,133 cases of severe acute osteomyelitis, divided into the survivor group (1,025 cases) and the non-survivor group (108 cases). Significant differences were observed between the two groups in terms of age, hypertension, sepsis, renal injury, and various laboratory indicators, including WBC, PLT, Ca2+, CRP, hemoglobin, albumin, and creatinine (P<0.05). However, no significant differences were found in race, gender, marital status, detection of wound microbiota, blood sugar, lactate, and ALP levels. A multivariate COX proportional hazards model was constructed using age, hypertension, sepsis, Ca2+, creatinine, albumin, and hemoglobin as variables. The results revealed that hypertension and sepsis had a significant impact on survival time (HR=0.514, 95% CI 0.339-0.779, P=0.002; HR=1.696, 95% CI 1.056-2.723, P=0.029). Age, hemoglobin, Ca2+, albumin, and creatinine also showed significant effects on survival time (P<0.05). However, no statistically significant impact on survival time was observed for the other variables (P>0.05). To predict the survival time, a nomogram was developed using the aforementioned indicators and achieved an AUC of 0.841. The accuracy of the nomogram was further confirmed by the ROC curve and calibration curve.
CONCLUSION: According to the findings, this study establishes that a reduction in serum calcium levels serves as a distinct and standalone predictor of mortality among individuals diagnosed with severe acute osteomyelitis during their stay in the Intensive Care Unit (ICU) within a span of two years.
Dual-therapy with a response-guided treatment duration with Alisporivir 400 mg BID and RBV for 12 or 24 weeks (Treatment period 1). Patients who were considered treatment failures were to be treated with peg-IFNα2a/RBV 800 mg daily for 24 weeks in Treatment period 2 (Roll-over treatment arm).
The invention relates to a construct of a fusion gene prokaryotic carrier of an IL-24 and an EGF and the application, which comprises a fusion gene of the IL-24 and the EGF, a prokaryotic expression vector of the fusion gene of the IL-24 and the EGF, a fusion protein of the IL-24 and the EGF. The construct of a fusion gene prokaryotic carrier of the IL-24 and the EGF is characterized in that the nucleotide sequence of the fusion gene of the IL-24 and the EGF is listed as SEQ ID No. 1, the prokaryotic carrier of the fusion gene of the IL-24 and the EGF has a nucleotide sequence showed as SEQ ID No. 1, the fusion protein of the IL-24 and the EGF has a nucleotide sequence code tabled as SEQ ID No. 1. The construct of a fusion gene prokaryotic carrie proves that the fusion protein of the IL-24 and the EGF is applicable to cure a cell lung cancer and greatly improves the operation of the IL-24 to inhibit the cancer cell from growing. The onstruct of a fusion gene prokaryotic carrier of an IL-24 and an EGF has the advantages of enabling the IL-24 and the EGF to develop the biological function, enhancing the targeting to the tumor cells, adopting the reliable and stable purifying process with high efficiency, which is applicable to the industrial production.
An edible chia oil nanoemulsion, rich in omega-3, with a high physical and oxidative stability, high bioaccessibility of omega-3 fatty acids and preparation methods. In particular, it discloses a chia oil nanoemulsion comprising between 10% and 20% of chia oil ( Salvia hispanica L. ), between 2% and 5% of polysorbate, between 0.5% and 5% of at least one emulsifier other than the polysorbate, between 0.05% and 0.2% of at least one antioxidant and water. In some specific preparations, the chia oil nanoemulsion of this invention may also comprise at least one pH modifier. In other specific preparations, the chia oil nanoemulsion of this invention may also comprise one or more polysaccharides. In other specific preparations, the chia oil nanoemulsion of this invention may also comprise one or more sugars. Also, edible formulations are disclosed, comprising chia oil nanoemulsions and, in particular, transparent drinks and desserts, such as juices and jellies with such nanoemulsions.
BACKGROUND AND PURPOSE: The diagnosis and management of acute fetal posterior cerebral artery occlusion are challenging. While endovascular treatment is established for anterior circulation large vessel occlusion stroke, little is known about the course of acute fetal posterior cerebral artery occlusions. We report the clinical course, radiological findings and management considerations of acute fetal posterior cerebral artery occlusion stroke.
METHODS: We performed a retrospective review of consecutive patients presenting with acute large vessel occlusion who underwent cerebral angiogram and/or mechanical thrombectomy between January 2015 and January 2021. Patients diagnosed with fetal posterior cerebral artery occlusion were included. Demographic data, clinical presentation, imaging findings and management strategies were reviewed.
RESULTS: Between January 2015 and January 2021, three patients with fetal posterior cerebral artery occlusion were identified from 400 patients who underwent angiogram and/or mechanical thrombectomy for acute stroke (0.75%). The first patient presented with concomitant fetal posterior cerebral artery and middle cerebral artery occlusions. Thrombectomy was performed with recanalisation of the fetal posterior cerebral artery but the patient died from malignant oedema. The second patient presented with isolated fetal posterior cerebral artery occlusion. No endovascular intervention was performed and the patient was disabled from malignant posterior cerebral artery infarct. The third patient presented with carotid occlusion and was found to have fetal posterior cerebral artery occlusion after internal carotid artery recanalisation. No further intervention was performed. The patient was left with residual contralateral homonymous hemianopia and mild left sided weakness.
CONCLUSION: Fetal posterior cerebral artery occlusion is a rare, but potentially disabling, cause of ischaemic stroke. Endovascular treatment is feasible. Further investigation is needed to compare the efficacy of medical versus endovascular management strategies.
Half of the participating hospitals will be in the control group for the first 6 months. The control group will undergo the intervention in the second 6 months.
The present invention discloses Fc fusion protein for human EPO with bioactivity which is similar to and higher than that of rHuEPO on the basis of moles. The HuEPO-L-vFc fusion protein contains human EPO, approximate 20 or fewer than 20 flexible peptide joints for amino acid and a human IgG Fc variant. The Fc variant has no cracking performance and has a minimal bad Fc-mediating side effect. The present invention also discloses a method for preparing or producing the fusion protein in a high expression level. The HuEPO-L-vFc fusion protein has the advantages of extension of blood serum half life and bioactivity increase. Consequently, pharmacodynamics and drug effects are improved, and a required injection time number within treatment time is few.
Body embalming, a practice with deep historical roots across various cultures, forms the backbone of contemporary human body donation educational programmes. In this study, we explored current embalming practices within six South African human anatomical dissection programmes, focusing on the use and volumes of key chemicals-formalin, phenol, and alcohol-and their associated health risks and potential toxicity. We measured and compared aspects of embalming practices such as the duration of body preservation and the annual intake of bodies. Variations in embalming practices and chemical ratios across different South African universities were found. However, the consistent use of formalin, phenol and alcohol were observed across all six programmes. Formaldehyde concentrations used in South African dissection programmes were within the generally acceptable international range. Regarding arterial embalming, South African dissection programmes showed widespread adherence to international embalming practices, with one programme using a substantially lower concentration of formalin. The dual nature of formaldehyde as both an effective preservative and a recognised carcinogen was underscored in relation to human health regarding chemical toxicity. Phenol, like formaldehyde, was consistently used as it is important for the inhibition of bacterial and fungal growth. Alcohol was also consistently used, but there was much greater variation in its volume across South African institutions. Our data showed a slight positive relationship between storage duration and the volumes of formalin and phenol in human embalming fluid. South African regulators enforce stricter exposure limits than those set by the World Health Organisation and various European agencies. While South African institutions operate within internationally acceptable ranges of chemical use that both maximise preservation and minimise toxicity, we acknowledge that these data are preliminary. Further investigation is encouraged to ensure embalming practices effectively protect all those involved and support the educational goals of human anatomical dissection programmes in South Africa.
PURPOSE:To produce a white material which has capability of intercepting ultraviolet rays and a high transmittance of visible rays in a good balance without undergoing degradation with time in these properties and is excellent in storage stability. CONSTITUTION:The title oxide comprises 100 pts.wt. zinc oxide and at least one oxide selected from the group consisting of 0.01-5.0 pts.wt. lanthanum oxide, 0.001-5.0 pts.wt. cerium oxide, 1.0-10.0 pts.wt. iron oxide, 1.0-10.0 pts.wt. cobalt oxide, 1.0-10.0 pts.wt. nickel oxide, 0.1-30.0 pts.wt. titanium oxide, and 0.1-30.0 pts.wt. aluminum oxide and has a surface treated with a silicone oil or a fatty acid.
Participants received SC doses of lademirsen 110 mg QW during the 48 weeks of DB treatment period. Participants who completed DB treatment period entered in OLE treatment period and continued the same lademirsen treatment in OLE period for an additional 48 weeks (i.e., up to Week 96).
Participants in this group will receive standard wound disinfection and initial postoperative care with dressings applied immediately after their gastrointestinal tumor surgery. However, 48 hours post-surgery, these dressings will be removed and the wounds will be left exposed without any further dressing. This arm aims to evaluate the outcomes of wound healing, pain levels, and healthcare costs when the surgical wound is kept open postoperatively, in contrast to traditional dressing methods.
PURPOSE: To obtain a hair cosmetic having excellent stability and conditioning effect by including a carboxylic acid-modified silicone and a cationic polymer. CONSTITUTION: This hair cosmetic contains an organo(poly)siloxane having at least a carboxyl group in a molecule and expressed by the formula (R<1> is a 1-22C alkyl, a 1-22C alkoxy or phenyl, etc.; R<2> -R<4> are each a 1-22C alkyl, a 1-22C alkoxy or phenyl, etc.; x and y are each 0-1000) in an amount of 0.1-20wt.% and a cationic polymer in an amount of 0.01-5wt.%. The compound of the formula and the cationic polymer are contained in the cosmetic at a weight ratio of 1000/1-5/1. By jointly using the compound of the formula and the cationic polymer, the two components are stable in storing and both remain on a hair with aggregating in rinsing after washing, and the compound of the formula forms scum by a metallic ion in the city water, then suitable dry feeling and high conditioning effect are obtained.  The cosmetic is formed to a shampoo, a rinse or a treatment, etc., especially water-based product such as hair cleaning agent is preferable.
PURPOSE:To make it possible to calculate the quantity of a gamma-Sm-a1-antitrypsin composite (gamma-Sm-a1AT) by using an anti-gamma-seminoprotein (gamma-Sm) antibody and an anti-a1-antitrypsin antibody. CONSTITUTION:The titled method can be performed by a sandwich immunoassay method. For example, anti-gamma-Sm antibody is adsorbed by or bonded to an insoluble carrier to form an insolubilized antibody. An anti-a1-antitrypsin antibody is labelled with a marker such as enzyme, an radioactive isotope or a fluorescent substance to obtain a labelled antibody. These antibodies are subjected to the antigen-antibody reaction with the gamma-Sm-a1AT composite in a specimen to be examined and the quantity of said composite can be calculated from the quantity of the bonded marker. Contrarily, the anti-a1-antitrypsin antibody may be converted to an insolubilized antibody while the anti-gamma-Sm antibody may be used as a marked antibody.
MBSR (mindfulness-based stress reduction) is a group-based, 8-week program that was developed at the University of Massachusetts Stress Reduction Clinic under the direction of Jon Kabat-Zinn. MBSR is comprised of a structured, developmentally sequenced curriculum that uses a group format to experientially instruct participants in the practice of mindfulness meditation and mindful Hatha yoga. Each session includes different forms of meditation practice, such as cultivating awareness of thoughts, feelings and bodily sensations, and learning to incorporate this awareness during stressful emotional and/or physical life situations. Lesson activities include the following: (1) mindful meditation (e.g., awareness of breathing, body scan, sitting, walking); (2) yoga; and (3) group discussion.
The safety and effectiveness of SEIZALAM for the treatment of status epilepticus was established in a multi-center, randomized, double-blind (double-dummy), active-control trial comparing midazolam administered intramuscularly (IM) via an auto-injector to lorazepam administered intravenously (IV). Patients meeting the diagnosis of status epilepticus, with continuing convulsive seizure activity after the arrival of paramedics, were eligible for enrollment. The ITT population consisted of 893 patients who were randomized to receive either IM midazolam (n=448) or IV lorazepam (n=445). Following randomization, each patient received study treatments administered by a healthcare professional (e.g., paramedic) prior to arrival at a hospital. According to the double-dummy design, adult patients received 10 mg IM midazolam followed by IV placebo or received IM placebo followed by 4 mg IV lorazepam. The primary efficacy endpoint was the termination of convulsive seizure activity (without the need for rescue medication) prior to arrival at the emergency department (ED) as determined by the ED attending physician. A statistically significantly higher percentage of midazolam-treated patients met the primary efficacy endpoint, as shown in Table 2.
Patients receive white button mushroom extract PO BID on day 1. Treatment repeats every 4 weeks for cycles 1-3 then every 12 weeks for cycles 4-6 (36 weeks) in the absence of disease progression or unacceptable toxicity.
FIELD: medicine. ^ SUBSTANCE: invention relates to medicine, namely to experimental nephrology and can be used for prevention of systemic amyloidosis and its nephropathic form in experimental animals during its modelling. For this purpose native egg albumen is introduced to old rats subcutaneously in dose 0.025 ml/g of body weight. Simultaneously with native egg albumen as amyloidoprotective medication used is medium-mineralised sulphide mineral water. Mineral water is introduced to rats daily via probe into stomach in dose 10 ml/kg during for 60 days. ^ EFFECT: extension of possibilities of preventing systemic amyloidosis and its nephropathic form. ^ 1 ex, 2 tbl, 4 dwg
Patients receive sitravatinib PO QD on days 1-14 and receive nivolumab IV over 60 minutes on day 1 starting cycle 2. Cycles repeat every 14 days for cycles 1-6 and then every 28 days for subsequent cycles in the absence of disease progression or unacceptable toxicity. Patients who receive at least 6 infusions of nivolumab with no DLTs related to nivolumab, may then receive nivolumab every 4 weeks.
Hyperkalemic participants were randomized to Dichlorphenamide for a 9 week double-blind phase. All participants then received Dichlorphenamide for a 52 week open-label phase.
Three subjects will receive a single dose of 3 mg/kg dabrafenib on Day 1 and repeat dose will begin from Day 2, evenly divided in two daily doses. Once all 3 subjects have been fully evaluated for the first 28 days (including Day 15 PK) and no DLTs are observed, a next subject will be enrolled at the next higher dose levels (i.e., dose escalation to 3.75 mg/kg \[+1\] and may be further to 4.5 mg/kg \[+2\] and so on). If all 3 subjects have not been fully evaluated for the first 28 days or 1 DLT occurred, the fourth subject will be enrolled at the same dose level. If 2 or more DLTs are observed, the next subject will be enrolled at the next lower dose level (i.e., de-escalated to 2.25 mg/kg \[-1\] and may be further to 1.5 mg/kg \[-2\]). Similarly, the process is repeated for the fifth and sixth subjects in a cohort. All subjects will receive treatment till end of study.
BACKGROUND: Hepatocellular carcinoma (HCC) stands as the prevailing manifestation of primary liver cancer. Previous studies have implicated ARHGEF39 in various cancer progression processes, but its impact on HCC metastasis remains unclear.
METHODS: Bioinformatics analysis and qRT-PCR were employed to test ARHGEF39 expression in HCC tissues and cells, identified enriched pathways associated with ARHGEF39, and investigated its regulatory relationship with E2F1. The impact of ARHGEF39 overexpression or knockdown on cellular phenotypes in HCC was assessed through the implementation of CCK-8 and Transwell assays. Accumulation of neutral lipids was determined by BODIPY 493/503 staining, while levels of triglycerides and phospholipids were measured using specific assay kits. Expression of E-cadherin, Vimentin, MMP-2, MMP-9, and FASN were analyzed by Western blot. The interaction between ARHGEF39 and E2F1 was validated through ChIP and dual-luciferase reporter assays.
RESULTS: Our study demonstrated upregulated expression of both ARHGEF39 and E2F1 in HCC, with ARHGEF39 being associated with fatty acid metabolism (FAM) pathways. Additionally, ARHGEF39 was identified as a downstream target gene of E2F1. Cell-based experiments unmasked that high expression of ARHGEF39 mediated the promotion of HCC cell viability, migration, and invasion via enhanced FAM. Moreover, rescue assays demonstrated that the promotion of HCC cell metastasis by high ARHGEF39 expression was attenuated upon treatment with Orlistat. Conversely, the knockdown of E2F1 suppressed HCC cell metastasis and FAM, while the upregulation of ARHGEF39 counteracted the repressive effects of E2F1 downregulation on the metastatic potential of HCC cells.
CONCLUSION: Our findings confirmed the critical role of ARHGEF39 in HCC metastasis and unmasked potential molecular mechanisms through which ARHGEF39 fostered HCC metastasis via FAM, providing a theoretical basis for exploring novel molecular markers and preventive strategies for HCC metastasis.
PURPOSE:To enable advantageous practice of an immunological searching method, analysis of relationship between a human monooxygenase and a cancerous change, etc., by using an antimonooxygenase.cytochrome P-450 monoclonal antibody having reactivity with human in vivo ingredients. CONSTITUTION:A purified human cytochrome(Cyt.) P-450 obtained from human specimen viscera, etc., is administered to a mouse to provide a hybridoma by fusion of a splenic cell from the immunized animal to a myelomatous cell. A culture supernatant of the resultant hybridoma is then used to prepare a monoclonal antibody. The obtained monoclonal antibody capable of recognizing a monooxygenase and proteins related thereto is used in a method for measuring in vivo ingredients according to an immunological method using the antibody. Furthermore, the aforementioned antibody is used in an immunohistochemical method for searching a test specimen of the presence of the monooxygenase and related proteins in tissues thereof, a drug missile employing the above-mentioned antibody as a carrier for an anticancer agent or carcinostatic agent, judgment of diseased parts, such as progressive cancer, for imaging diagnosis, etc.